Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 620-056-5 | CAS number: 874195-61-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30 May - 29 Jun 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3200 (Repeated Dose Dermal Toxicity -21/28 Days)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- ORSZÄGOS GYÖGYSZERESZETI INTEZET, National Institue of Phyrmacy, Budapest, Hungary
Test material
- Reference substance name:
- N-[2-(4,6-dimethoxy-1,3,5-triazine-2-carbonyl)-6-fluorophenyl]-1,1-difluoro-N-methylmethanesulfonamide
- EC Number:
- 620-056-5
- Cas Number:
- 874195-61-6
- Molecular formula:
- C14H13F3N4O5S
- IUPAC Name:
- N-[2-(4,6-dimethoxy-1,3,5-triazine-2-carbonyl)-6-fluorophenyl]-1,1-difluoro-N-methylmethanesulfonamide
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:Wistar rats
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany
- Age at study initiation: approx. 9 weeks
- Weight at study initiation: 302-341 g (males), 195-236 g (females)
- Housing: 5 animals of the same sex per cage in type II and/or III polycarbonate cages; individual caging was employed after the onset of treatment to avoid ingestion of the jackets/bandage/test item between the animals housed in the same cage; deep wood sawdust bedding was used (Lignocel® Hygienic Animal Bedding, J. Rettenmaier & Söhne GmbH+Co.KG, Germany).
- Diet: ssniff® SM R/M “Autoclavable Complete diet for Rats and Mice – Breeding and Maintenance” (Ssniff Spezialdiäten GmbH, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 16 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.6–24.3
- Humidity (%): 30-65
- Air changes (per hr): 15-20
- Photoperiod (hrs dark/hrs light): 12/12
IN-LIFE DATES: From: 2012-05-31 To: 2012-06-29
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- other: unchanged (the test substance was moistened sufficiently with water (no more than 300 µL))
- Details on exposure:
- TEST SITE
- Area of exposure: clipped flank (area starting approximately at the scapulae (shoulders) to the wing of the ileum (hipbone) and half way down the flank on each side of the animal
- % coverage: 10% of body surface area
- Type of wrap if used: test substance was held in contact with the skin with a porous gauze dressing (less than or equal to 8 plies); the test site was further covered with non-irritating tape to retain the gauze dressing
- Time intervals for shavings or clipplings: approximately 24 hours before the test (repeated as required and as practical depending upon hair growth of individual animals and/or the effects observed)
REMOVAL OF TEST SUBSTANCE
- Washing (if done): test substance was gently wiped from the skin with lukewarm water
- Time after start of exposure: 6 hours
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes (Lomir jackets with inserts and collars as required), but no complete immobilization was used - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily (7 days/week)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
250, 500 and 1000 mg/kg bw/day
Basis:
- No. of animals per sex per dose:
- 10
- Control animals:
- other: control animals were similarly treated with gauze patches and restrainers (Lomir jackets with inserts and collars).
- Details on study design:
- - Route selection rationale: The dermal route was selected to provide information for hazard assessment as skin contact is one of the possible routes of human exposure.
- Dose selection rationale: Based the absence of signs of toxicity following a single dermal application of 2000 mg/kg bw for 24 hours to the shaved flank of male and female Wistar rats, the applied concentrations were selected.
- Animal assignment: according to body weight
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: inspection for morbidity and mortality: twice daily, general clinical observation: at least daily, detailed examinations performed outside the home cage: prior to first exposure and and once weekly thereafter
DERMAL IRRITATION: Yes
- Time schedule for examinations: daily, following patch removal
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: prior to treatment and during the last week of exposure (Day 26)
- Dose groups that were examined: prior to treatment: all animals, Day 26: control and high-dose groups (as no effects were observed in the high-dose group, the low- and mid-dose groups were not further examined)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to necropsy on Day 28
- Anaesthetic used for blood collection: Yes (pentobarbital)
- Animals fasted: Yes
- How many animals: all animals
- Parameters checked: red blood cell count (RBC), haemoglobin concentration (Hgb), haematocrit (Het), mean corpuscular (erythrocyte)
volume (MCV), mean corpuscular (erythrocyte) haemoglobin (MCH), red cell (erythrocyte) volume (RDW), platelet (thrombocyte) count (Plt), mean platelet (thrombocyte) volume (MPV), reticulocyte count (RETIC), white blood cell (leukocyte) count (WBC); coagulation: activated partial thromboplastin time (APTT), prothrombin time (PT)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to necropsy on Day 28
- Animals fasted: Yes
- How many animals: all animals
- Parameters checked: glucose, total bilirubin concentration (T-BIL), urea, cholesterol (Chol), triglycerides (TRIG), creatinine concentration (CREAT), phosphorus concentration (Phos), sodium, potassium, calcium and chloride concentrations, total protein concentration (Tot Prot), albumin (Alb), Alb/glob ratio (A/G), aspartate aminotransferase activity (U/L), alanine aminotransferase activity (U/L), alkaline phosphatase activity (ALKP), gamma glutamyltransferase activity (GGT), bile acids
URINALYSIS: Yes
- Time schedule for collection of urine: prior to necropsy on Day 28
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked: leukocyte (LEU), nitrite (NIT), pH, protein (Pro), glucose (GLU), urobilinogen (UBG), bilirubin (BIL), ketones (KET), blood/erythrocytes (BLD/ERY), specific gravity (SG), sediment (SED), volume (VOL)
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during the last week of exposure (on Day 26)
- Dose groups that were examined: all dose groups
- Battery of functions tested: functional observation battery / grip strength / motor activity / other: measurements of landing foot splay, sensory reactivity
OTHER:
Examination of vaginal smears prior to necropsy - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Cranium, thoracic and abdominal cavities were opened and the appearance of the tissues and organs were observed macroscopically.
Organs checked: brain, epididymides, heart, kidney, liver, spleen, prostate incl. seminal vesicles with coagulating glands, testes, thymus, uterus incl. cervix, adrenals, ovaries, pituitary and thyroids with parathyroids
HISTOPATHOLOGY: Yes (full histopathology was performed in the control and high-dose group and in all organs with macroscopic abnormalities.
Organs checked: gross findings, larynx, skeletal muscle (quadriceps), treated skin area, liver (all dose groups), skin and subcutis (inguinal), adrenals, lungs with bronchi, small intestine, lymph nodes, spinal cord, aorta, mammary gland, spleen, brain, nose/nasal cavity, sternum with marrow, epididymides, ovaries with oviduct, stomach, eyes with the optic nerves, pharynx, testes, external lachrymal glands, pancreas, thymus, oesophagus, pituitary, thyroid with parathyroids, femur with marrow, prostate, tongue, harderian glands, salivary glands, trachea, heart, sciatic nerve, urinary bladder, kidneys, seminal vesicles with coagulating glands, uterus, large intestine, vagina - Statistics:
- Mean and standard deviations were calculated and statistical analysis was performed using SPSS PC+4.0. The heterogeneity of variance between groups was checked by Bartlett’s homogeneity of variance test. Where no significant heterogeneity was detected, a one-way analysis of variance was carried out. If the obtained result was positive, Duncan’s Multiple Range test was used to assess the significance of inter-group differences. Where significant heterogeneity was found, the normal distribution of data was examined by Kolmogorov-Smirnov test. If the data was not normal distributed, the non-parametric method of Kruskal-Wallis One-Way analysis of variance was used. If there was a positive result, the inter-group comparisons were performed using Mann-Whitney U-test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- all dose groups: slight skin lesions (scab and scar) were observed due to friction with the restraint (non-adverse)
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- 500 mg/kg bw/day: transient statistically increased body weight in females during Week 3 (non-adverse)
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- males: all dose groups: lower PTT values; 500 mg/kg bw/day: lower WBC counts and higher platelet counts, 1000 mg/kg bw/day: higher platelet counts (non-adverse); females: 250 mg/kg bw/day: lymphocyte count statistically different (non-adverse)
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: increased cholesterol in males and females: all dose groups: increased creatinine (non-adverse)
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- males, all dose group: slight differences in urine specific gravity (non-adverse)
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- grip strength test: increased values for males from all dose groups and high-dose females (non-adverse)
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: increased relative liver weight in males and females, increased weight of thyroid glands in females (non-adverse)
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- all dose groups: incidental gross abnormalities (non-adverse)
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: minimal centrilobular hepatocellular hypertrophy and minimal/mild diffuse hepatocellular vacuolation in males and females
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No mortality or clinical signs of toxicity were observed during the study period. No signs of skin irritation were noted. Occasionally slight skin lesions (scab and scar) were observed with similar low incidence across the groups in males (2/10, 1/10, 1/10 and 0/10) and females (3/10, 0/10, 1/10 and 0/10) in the control, low, mid and high dose groups, respectively. These observations were ascribed to minor effects of friction with the restraint and not related to the test item.
BODY WEIGHT AND WEIGHT GAIN
No treatment-related effect on body weight and weight gain was noted. Due to the transient occurence, the statistically significant higher body weight gain in mid-dose females only during Week 3 (p < 0.05) is not considered as toxicologically significant or related to treatment (Table 1).
FOOD CONSUMPTION
Food consumption was comparable among the groups.
OPHTHALMOSCOPIC EXAMINATION
Opthalmology did not reveal differences between control and test groups.
HAEMATOLOGY
Variations, attaining statistical significance were noted in males in lower WBC counts in the mid-dose group (p < 0.05) and higher platelet counts in the mid- and high-dose groups (p < 0.05 and p < 0.01, respectively). Lower PTT values were noted in all treated males, due to relatively high variations in the control individual values. Furthermore, statistical difference (p < 0.05) was noted for relative lymphocyte count in low-dose females (Table 2). As all parameters fall within the normal physiological and historical control ranges for the age, strain and sex of rats, these effects are not considered as adverse.
CLINICAL CHEMISTRY
High-dose males and females revealed a slight but statistically significant increase in cholesterol concentration around 23-24% , respectively. In mid-dose females, 2/10 animals reached cholesterol values above the control range. As both values still remained within the physiological range, the effect in the mid-dose group is not considered as adverse. Creatinine levels were slightly increased in all dose groups. In the high-dose group, no more than 17-19% difference was noted without any effect on urea concentration in males. As the observed changes in creatinine were of small magnitude, the mean and individual values remained within normal ranges and no consequent effect on urea concentration was observed, the effect on creatinine is not considered as adverse (Table 3). Other minor variations noted in chloride concentration, total protein or urea achieved statistical significance occasionally (Table 2). Due to the absence of consistent patterns or other correlates, these changes were regarded as incidental or individual findings, and are therefore not considered as treatment-related or of toxicological significance.
URINALYSIS
Slight differences were observed in urine specific gravity in males from all dose groups, which attained statistical significance in low- and high-dose males (p < 0.05 and p < 0.01, respectively). As no dose-dependency was present, and due to the lack of any evident renal pathology, these observations were regarded as incidental findings.
No abnormalities were observed in the remaining evaluated parameters.
NEUROBEHAVIOUR
Increased values were noted in grip strength tests for hind limb in all treated male groups and in females of the high-dose group compared to the controls. The differences reached statistical significance in mid-dose males and high-dose females (p < 0.05), but were considered to be without toxicological significance. Increased vocalization was observed on occasion throughout all the dose groups at the modified Irwin test (functional observation battery). However, as there were no treatment-related differences to the control, and the incidence was similar in all groups and no dose-, or gender-related responses were noted, these variations were considered to be without toxicological significance and within the normal biological variation with respect to behaviour, reactions to different type of stimuli or manipulations. Thus, no toxicologically significant changes in behaviour, general physical condition, or neurobehaviour (including the reactions to different type of stimuli, grip strength or motor activity) were noted on Day 26.
ORGAN WEIGHTS
Test item related organ weight differences were found in liver (males and females) and thyroid (females) weights in the high-dose group. As the increased liver weights in low- and mid-dose animals were of low magnitude (3-10%) without any morphological change or adverse effect in clinical pathology, they were considered as adaptive (Table 1). Thyroid weights were dose-dependently increased in females of the mid-and high-dose group. The increase in the mid-dose group was of low magnitude, with almost all individual weights lying in the control range. Compared to control, the thyroid weights in the high-dose females were significantly elevated by approximately 22% (absolute value) and 19-21% (relative values). 4 of 10 individual values were above the control, but within the physiological range. As the changes were not associated with any morphological change suggesting increased TSH activity or utilization of thyroglobulins, the observations on the thyroid weights were not considered adverse. Absolute kidney weights were slightly increased in all treatment groups of both sexes by approximately 4-9%. Differences were statistically significant in high-dose males. However, as the differences remained minor and were within the physiological range, they were not considered as adverse. No biologically significant differences were observed among the groups in the weights of the remaining evaluated organs compared with the control, although statistically significant variations without trend were noted (i.e thymus). Therefore, in the absence of a dose- or gender-related response, or consistent correlation with histopathological results, these variations were not considered to reflect an adverse effect.
GROSS PATHOLOGY
Multifocal/focal dark red discoloration of the thymus was observed in 1/10 control female and 2/10 high-dose males which was regarded as terminal procedure related. Furthermore, multifocal/focal dark red/brown discolouration of glandular mucosa of the stomach (1/10 mid-dose female), enlarged adrenal (1/10 mid-dose female), unilateral enlargement of the testes (1/10 mid-dose male) were observed. Due to the low incidence and missing dose-response, these findings are regarded as incidental. Unilateral pelvic dilatation of the kidney (2/10 high-dose males) or dilated uterine horns (1/10 control and 2/10 high-dose females) were observed in single animals. As these variations represent common observations in Wistar rats, they are not interpreted as incidental and not adverse due to the incidence. In addition, at external examination, small scars, or scabs on the dorsal neck, thoracic region and on forelimbs were observed with low incidence in control and mid-dose males which were regarded as procedure related.
HISTOPATHOLOGY: NON-NEOPLASTIC
Test item-related findings were observed in the liver of high-dose males and females visible as minimal/mild, periportal/diffuse hepatocellular vacuolation which was found in 3/10 males and females. Minimal centrilobular hepatocellular hypertrophy was observed in 3/10 males and in 2/10 females. As the changes were correlated with increased organ weights, they are considered as treatment-related. No similar observations were made in animals of the lower dose groups. Examination of the skin revealed signs of minimal, multifocal hyperkeratosis/parakeratosis which was observed in 7/10 and 3/10 high-dose males and females, respectively, in 1/10 mid-dose males and in 3/10 control females (skin in the low- and mid-dose animals were not examined, except necropsy findings). In addition, focal purulent inflammation and mixed cellular infiltrate in the skin were observed in 3/10 control females. As these abnormalities occured also in the control group, the changes were considered to be procedure- and not test item-related. Changes observed in various organs including the prostate (only in the control), kidney (1/10 control and 1/10 high-dose male and 1/10 control female), testis (1/10 control and 1/10 mid-dose male, but not in the high-dose group) or thymus (2/10 control and 2/10 high-dose males and 1/10 control female) were regarded as incidental because of the randomly distribution across control and treated groups. Microscopic findings in the uterus (like luminal dilatation and glandular proliferation) seen in 1/10 control and 2/10 high-dose females were related to typical physiological changes observed during oestrus cycle in female rats and are therefore not toxicologically significant and/or associated with test item administration.
OTHER FINDINGS
Oestrus evaluation: All animals showed normal distribution of oestrus phases.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on adverse effects observed on the liver (minimal/mild, periportal/diffuse hepatocellular vacuolation and minimal centrilobular hepatocellular hypertrophy correlated with increased liver weight and increased cholesterol in both sexes)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Body weight [g]
Sex |
Dose group (mg/kg bw/day) |
Treatment day |
||||
0 |
7 |
14 |
21 |
27 |
||
Male |
Control |
319.3 ± 11.5 |
357.8 ± 17.2 |
383.6 ± 20.5 |
414.3 ± 23.4 |
423.1 ± 24.8 |
|
250 |
320.1 ± 10.0 |
361.9 ± 14.0 |
389.8 ± 19.3 |
422.3 ± 23.1 |
433.2 ± 23.6 |
|
500 |
318.0 ± 8.4 |
355.7 ± 9.6 |
381.1 ± 15.1 |
411.1 ± 14.3 |
419.5 ± 17.1 |
|
1000 |
319.9 ± 12.8 |
361.0 ± 15.5 |
389.7 ± 19.2 |
420.0 ± 28.0 |
427.6 ± 29.7 |
Female |
Control |
214.5 ± 11.9 |
228.3 ± 17.7 |
236.8 ± 20.5 |
243.7 ± 17.5 |
246.1 ± 20.7 |
|
250 |
215.0 ± 10.8 |
232.0 ± 14.2 |
244.9 ± 23.9 |
253.4 ± 24.1 |
259.0 ± 26.4 |
|
500 |
216.2 ± 10.7 |
228.1 ± 13.6 |
238.4 ± 14.9 |
255.5 ± 20.7 |
254.8 ± 28.3 |
|
1000 |
210.2 ± 10.8 |
227.0 ± 13.1 |
241.5 ± 11.6 |
253.2 ± 11.7 |
252.2 ± 10.9 |
Table 2: Haematology and Clinical Chemistry: mean values of altered parameters on Day 28.
Sex |
Dose group (mg/kg bw/day) |
Haematology |
Clinical Chemistry |
Urinalysis |
|||||
WBC [K/µL] |
PLT [K/µL] |
PTT [seconds] |
LYMPH [%] |
Chloride [mmol/L] |
Tot. Prot. [g/L] |
Urea [mmol/L] |
Specific Gravity |
||
Male |
Control |
4.533 ± 1.333 |
1062.5 ± 94.2 |
22.01 ± 1.19 |
66.130 ± 6.815 |
103.51 ± 1.20 |
54.78 ± 1.82 |
5.749 ± 0.868 |
1.0091 ± 0.0007 |
250 |
5.271 ± 2.260 |
1035.8 ± 188.4 |
21.18* ± 0.47 |
67.140 ± 3.940 |
101.71** ± 0.94 (DN) |
54.96 ± 1.71 |
5.323 ± 0.474 |
1.0107* ± 0.0021 |
|
500 |
3.370* ± 0.796 (U) |
1157.1* ± 65.6 (U) |
20.97* ± 0.93 (DN) |
65.150 ± 7.770 |
102.89 ± 1.20 |
56.23 ± 1.47 |
6.040 ± 0.599 |
1.0109 ± 0.0028 |
|
1000 |
4.982 ± 1.786 |
1217.9** ± 112.8 (U) |
21.26 ± 0.69 |
71.380 ± 4.818 |
103.29 ± 1.95 |
56.72* ± 2.21 (DN) |
5.522 ± |
1.0125** ± 0.0030 |
|
Female |
Control |
1.818 ± 1.003 |
1144.4 ± 209.4 |
23.03 ± 0.78 |
65.200 ± 10.071 |
103.47 ± 1.41 |
58.01 ± 2.28 |
6.748 ± 0.834 |
1.0143 ± 0.0075 |
250 |
2.517 ± 1.131 |
1119.4 ± 138.3 |
23.08 ± 0.95 |
74.250* ± 6.945 (DN) |
102.83 ± 1.72 |
56.84 ± 1.29 |
5.957 ± 0.985 |
1.0115 ± 0.0037 |
|
500 |
2.181 ± 0.845 |
1153.6 ± 171.4 |
22.99 ± 1.30 |
72.770 ± 9.983 |
102.51 ± 1.36 |
59.25 ± 3.40 |
6.124 ± 1.116 |
1.0146 ± 0.0045 |
|
1000 |
1.614 ± 0.685 |
1072.0 ± 102.0 |
22.20 ± 0.77 |
68.940 ± 6.428 |
102.09 ± 1.68 |
60.33 ± 2.77 |
5.240** ± 0.482 (DN) |
1.0146 ± 0.0056 |
*: p < 0.05, **: p < 0.01
DN = Duncan's Multiple Range Test; U = Mann- Whitney U-Test
Table 3: Mean values of cholesterol and creatinine levels on Day 28.
|
Dose group (mg/kg bw/day) |
||||
Control |
250 |
500 |
1000 |
||
Males |
Cholesterol (mmol/L) |
1.64 |
1.56 |
1.75 |
2.04** (DN) |
Cholesterol (% difference) |
|
-5 |
7 |
24 |
|
Creatinine (µmol/L) |
53.3 |
57.7 |
60.1 |
63.2* (DN) |
|
Creatinine (% difference) |
|
8 |
13 |
19 |
|
Females |
Cholesterol (mmol/L) |
1.84 |
1.80 |
2.13 |
2.26** (U) |
Cholesterol (% difference) |
|
-2 |
16 |
23 |
|
Creatinine (µmol/L) |
48.7 |
53.0 |
53.5 |
56.9 |
|
Creatinine (% difference) |
|
9 |
10 |
17 |
*: p < 0.05, **: p < 0.01
DN = Duncan's Multiple Range Test; U = Mann- Whitney U-Test
Table 4: Mean weights of liver of males and females on Day 28.
|
Dose group (mg/kg bw/day) |
||||
Control |
250 |
500 |
1000 |
||
Males |
Liver weight (absolute [g]) |
10.8 |
12.0* |
11.4 |
12.2** (DN) |
Difference [%] |
|
11 |
6 |
13 |
|
Body weight relative [%] |
2.7 |
2.9** |
2.9* |
3.0** (DN) |
|
Difference [%] |
|
7 |
7 |
11 |
|
Brain relative [%] |
526 |
578* |
556 |
598** (DN) |
|
Difference [%] |
|
10 |
6 |
14 |
|
Females |
Liver weight (absolute [g]) |
6.64 |
7.32 |
7.66* |
7.87** (DN) |
Difference [%] |
|
10 |
15 |
19 |
|
Body weight relative [%] |
2.9 |
3.0 |
3.2** |
3.3** (DN) |
|
Difference [%] |
|
3 |
10 |
14 |
|
|
Brain relative [%] |
364 |
384 |
414* |
429** |
|
Difference [%] |
|
5 |
14 |
18 |
* = p < 0.05, ** = p < 0.01
DN = Duncan's Multiple Range Test
Table 5: Mean weights of kidneys and thyroids of males and females on Day 28.
Dose group (mg/kg bw/day) |
|||||
Control |
250 |
500 |
1000 |
||
Males |
Kidney weight (absolute [g]) |
2.66 |
2.83 |
2.76 |
2.87* (DN) |
Difference [%] |
|
6 |
4 |
8 |
|
Thyroid weight (absolute [g]) |
21.2 |
21.6 |
19.6 |
20.8 |
|
Difference [%] |
|
2 |
-8 |
-2 |
|
Females |
Kidney weight (absolute [g]) |
1.64 |
1.78 |
1.76 |
1.73 |
Difference [%] |
|
9 |
7 |
6 |
|
Thyroid weight (absolute [g]) |
16.7 |
17.3 |
18.9 |
20.3** (DN) |
|
Difference [%] |
|
4 |
13 |
22 |
|
|
Body weight relative [%] |
7.19 |
7.17 |
7.91 |
8.55** (DN) |
|
Difference [%] |
|
0 |
10 |
19 |
|
Brain relative [%] |
0.92 |
0.91 |
1.02 |
1.11** (DN) |
|
Difference [%] |
|
-1 |
11 |
21 |
* = p < 0.05, ** = p < 0.01
DN = Duncan's Multiple Range Test
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.